Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.

Saved in:
Bibliographic Details
Title: Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen presenting cells and drives anti-tumor responses in non-injected tumors in metastatic melanoma: A phase I/II study.
Authors: Bentebibel SE; The University of Texas MD Anderson Cancer Center Houston, Texas United States., McGrail DJ; Cleveland Clinic Cleveland, OH United States., Kochat V; The University of Texas MD Anderson Cancer Center Houston, Texas United States., Arslan E; The University of Texas MD Anderson Cancer Center Houston, Texas United States., Abdel-Wahab R; The University of Texas MD Anderson Cancer Center Houston, TX United States., Pazdrak B; The University of Texas MD Anderson Cancer Center United States., Murthy R; The University of Texas MD Anderson Cancer Center Houston, Texas United States., Tahon NHM; The University of Texas MD Anderson Cancer Center Houston United States., Cho SN; The University of Texas MD Anderson Cancer Center Houston United States., Duose DY; The University of Texas MD Anderson Cancer Center Houston, TX United States., Wani K; The University of Texas MD Anderson Cancer Center Houston, Tx United States., Liu J; The University of Texas MD Anderson Cancer Center Houston United States., Haymaker C; The University of Texas MD Anderson Cancer Center Houston, Texas United States., Gomez JA; The University of Texas MD Anderson Cancer Center Houston, TX United States., Sonnemann H; The University of Texas MD Anderson Cancer Center Houston, TX United States., Katailiha AS; The University of Texas MD Anderson Cancer Center Houston, TX United States., Nassif-Rausseo B; The University of Texas MD Anderson Cancer Center United States., Rahim M; Stanford University United States., Li I; Stanford University United States., Mayer AT; Stanford University Stanford, California United States., Yang X; Pyxis Boston United States., Hsu FJ; Pyxis Oncology San Carlos, CA United States., Zhang J; The University of Texas MD Anderson Cancer Center United States., Johnson DH; Ochsner Medical Center New Orleans, Louisiana United States., Amaria RN; The University of Texas MD Anderson Cancer Center Houston, TX United States., Glitza Oliva IC; The University of Texas MD Anderson Cancer Center Houston, Texas United States., Patel SP; University of Colorado Anschutz Medical Campus Aurora United States., Hwu P; Moffitt Cancer Center Tampa, FL United States., Elsayes KM; The University of Texas MD Anderson Cancer Center Pearland United States., Tawbi HA; The University of Texas MD Anderson Cancer Center Houston, Texas United States., Burks JK; The University of Texas MD Anderson Cancer Center Houston, TX United States., Bernatchez C; The University of Texas MD Anderson Cancer Center Houston, Texas United States., Davies MA; The University of Texas MD Anderson Cancer Center Houston, TX United States., Rai K; The University of Texas MD Anderson Cancer Center Houston, TX United States., Lizee G; The University of Texas MD Anderson Cancer Center Houston, TX United States., Ekmekcioglu S; The University of Texas MD Anderson Cancer Center Houston, TX United States., Diab A; Cleveland Clinic Cleveland United States.
Source: Cancer discovery [Cancer Discov] 2026 Apr 21. Date of Electronic Publication: 2026 Apr 21.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-25-1551